Generic Aponvie Availability
Last updated on Apr 10, 2025.
Aponvie is a brand name of aprepitant, approved by the FDA in the following formulation(s):
APONVIE (aprepitant - emulsion;intravenous)
-
Manufacturer: HERON THERAPS INC
Approval date: September 16, 2022
Strength(s): 32MG/4.4ML (7.2MG/ML) [RLD]
Is there a generic version of Aponvie available?
No. There is currently no therapeutically equivalent version of Aponvie available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aponvie. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Emulsion formulations of aprepitant
Patent 10,500,208
Issued: December 10, 2019
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): HERON THERAPEUTICS, INC.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent 10,624,850
Issued: April 21, 2020
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of aprepitant
Patent 10,953,018
Issued: March 23, 2021
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent 11,173,118
Issued: November 16, 2021
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Patent 11,744,800
Issued: September 5, 2023
Inventor(s): Ottoboni; Thomas B. et al.
Assignee(s): HERON THERAPEUTICS, INC. (San Diego, CA)Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓✓
- September 18, 2035
-
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Patent 11,878,074
Issued: January 23, 2024
Inventor(s): Ottoboni; Thomas B. et al.
Assignee(s): Heron Therapeutics, Inc. (San Diego, CA)Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Patent 12,115,254
Issued: October 15, 2024
Inventor(s): Ottoboni; Thomas B. et al.
Assignee(s): Heron Therapeutics, Inc. (San Diego, CA)Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Methods of use of emulsion formulations of an NK-1 receptor antagonist
Patent 12,115,255
Issued: October 15, 2024
Inventor(s): Ottoboni; Thomas B. et al.
Assignee(s): HERON THERAPEUTICS, INC. (San Diego, CA)Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of aprepitant
Patent 9,561,229
Issued: February 7, 2017
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓✓
- September 18, 2035
-
Emulsion formulations of aprepitant
Patent 9,808,465
Issued: November 7, 2017
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent 9,974,742
Issued: May 22, 2018
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of aprepitant
Patent 9,974,793
Issued: May 22, 2018
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Emulsion formulations of aprepitant
Patent 9,974,794
Issued: May 22, 2018
Inventor(s): Ottoboni Thomas B. & Han Han
Assignee(s): Heron Therapeutics, Inc.Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Patent expiration dates:
- September 18, 2035✓✓
- September 18, 2035
More about Aponvie (aprepitant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: NK1 receptor antagonists
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
